PMID- 25683856
OWN - NLM
STAT- MEDLINE
DCOM- 20150729
LR  - 20181113
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Print)
IS  - 0361-8609 (Linking)
VI  - 90
IP  - 6
DP  - 2015 Jun
TI  - High fluorescence in situ hybridization percentage of deletion 11q in patients 
      with chronic lymphocytic leukemia is an independent predictor of adverse outcome.
PG  - 471-7
LID - 10.1002/ajh.23978 [doi]
AB  - We have analyzed patients with previously untreated chronic lymphocytic leukemia 
      with del11q fluorescence in situ hybridization (FISH) abnormality (n = 196) in 
      this study. Detection of the 11q22.3 used a multicolor FISH technique. Patients 
      with del11q fell into two major FISH subsets-sole del11q (n = 64) and del11q with 
      del13q (n = 132). FISH subsets were compared using the median del11q FISH% (>58%, 
      high vs. </=58%, low). Overall survival (OS) and time to first treatment (TTFT) 
      were estimated using Kaplan-Meier plots (log rank). Multivariate analysis was 
      performed to assess the association between FISH% of del11q and outcomes. 
      Patients with sole del11q were similar to del11q with del13q in terms of TTFT and 
      OS. Patients with high FISH% of del11q had significantly shorter OS and TTFT as 
      compared with patients with low FISH%, particularly in sole del11q; this negative 
      impact of high FISH% of del11q on OS and TTFT was diminished with coexistent 
      del13q. In multivariate analysis, high FISH% of del11q was a significant 
      predictor for shorter OS and TTFT. A comparison of these del11q subsets with a 
      separate cohort of (n = 673) previously untreated patients with sole del13q 
      showed that the high FISH% del11q cohort had a significantly shorter TTFT and OS. 
      In addition, bulky disease by physical examination or computed tomography imaging 
      was infrequent at presentation in patients with del11q. High FISH% of del11q can 
      reliably discriminate higher risk patients with chronic lymphocytic leukemia. 
      Presence of coexistent del13q should be accounted for while prognosticating 
      patients with del11q.
CI  - (c) 2015 Wiley Periodicals, Inc.
FAU - Jain, Preetesh
AU  - Jain P
AD  - Department of Leukemia, the University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Keating, Michael
AU  - Keating M
AD  - Department of Leukemia, the University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Thompson, Phillip A
AU  - Thompson PA
AD  - Department of Leukemia, the University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Trinh, Long
AU  - Trinh L
AD  - Department of Leukemia, the University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Wang, Xuemei
AU  - Wang X
AD  - Department of Biostatistics, the University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Wierda, William
AU  - Wierda W
AD  - Department of Leukemia, the University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Ferrajoli, Alessandra
AU  - Ferrajoli A
AD  - Department of Leukemia, the University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Burger, Jan
AU  - Burger J
AD  - Department of Leukemia, the University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Kantarjian, Hagop
AU  - Kantarjian H
AD  - Department of Leukemia, the University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Estrov, Zeev
AU  - Estrov Z
AD  - Department of Leukemia, the University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Abruzzo, Lynne
AU  - Abruzzo L
AD  - Department of Hematopathology, the University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - O'Brien, Susan
AU  - O'Brien S
AD  - Department of Leukemia, the University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
LA  - eng
GR  - P01 CA081534/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
DEP - 20150330
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 11/*genetics
MH  - Chromosomes, Human, Pair 13/genetics
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics/*mortality
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Survival Rate
PMC - PMC4521389
MID - NIHMS690231
COIS- Conflict of interest: None of the authors report any competing conflicts of 
      interest.
EDAT- 2015/02/17 06:00
MHDA- 2015/07/30 06:00
PMCR- 2016/06/01
CRDT- 2015/02/17 06:00
PHST- 2015/02/08 00:00 [received]
PHST- 2015/02/10 00:00 [accepted]
PHST- 2015/02/17 06:00 [entrez]
PHST- 2015/02/17 06:00 [pubmed]
PHST- 2015/07/30 06:00 [medline]
PHST- 2016/06/01 00:00 [pmc-release]
AID - 10.1002/ajh.23978 [doi]
PST - ppublish
SO  - Am J Hematol. 2015 Jun;90(6):471-7. doi: 10.1002/ajh.23978. Epub 2015 Mar 30.